The stock of OncoCyte Corp (NYSEMKT:OCX) is a huge mover today! The stock increased 18.26% or $1.05 on November 23, hitting $6.8. About 85,795 shares traded hands or 379.25% up from the average. OncoCyte Corp (NYSEMKT:OCX) has risen 21.65% since April 22, 2016 and is uptrending. It has outperformed by 16.24% the S&P500.
The move comes after 8 months positive chart setup for the $229.09M company. It was reported on Nov, 24 by Barchart.com. We have $7.07 PT which if reached, will make NYSEMKT:OCX worth $9.16 million more.
Analysts await OncoCyte Corp (NYSEMKT:OCX) to report earnings on March, 29. They expect $-0.10 EPS, up 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.10 actual EPS reported by OncoCyte Corp for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.”
More notable recent OncoCyte Corp (NYSEMKT:OCX) news were published by: Quotes.Wsj.com which released: “News OncoCyte Corp.OCX” on August 05, 2012, also Businesswire.com with their article: “BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond to its Board of …” published on September 14, 2015, Businesswire.com published: “BioTime Completes Distribution of Approximately 4.75 Million Shares of …” on December 31, 2015. More interesting news about OncoCyte Corp (NYSEMKT:OCX) were released by: Globenewswire.com and their article: “OncoCyte Corporation Initiates Trading on the NYSE MKT” published on January 04, 2016 as well as Businesswire.com‘s news article titled: “BioTime Announces â€œWhen-Issuedâ€ Trading of Subsidiary OncoCyte Corporation in …” with publication date: December 30, 2015.
OCX Company Profile
OncoCyte Corporation (OncoCyte), incorporated on October 30, 2009, is a development-stage biotechnology firm focused in the field of regenerative medicine. The Firm is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. The Company’s initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.